QYUNS-B (02509) surged over 8% intraday, reaching a high of HK$22.15, hitting its highest level since October last year. The stock has accumulated nearly 40% gains over the past month. As of press time, it was up 5.42% to HK$21.4 with a turnover of HK$5.7078 million.
According to public information, QYUNS-B is a high-tech biopharmaceutical enterprise specializing in biological therapies for autoimmune and allergic diseases, possessing a completely independently developed drug pipeline and mature commercial-scale internal production capabilities. Based on comprehensive independent innovation capabilities, the company has formed a product pipeline containing multiple innovative varieties, with 1 variety already approved for market, 2 varieties in Phase III clinical trials, and 4 varieties in Phase II and Phase I clinical trials respectively. The indications cover four major disease areas including dermatology, rheumatology, respiratory, and digestive diseases such as psoriasis, atopic dermatitis, ankylosing spondylitis, systemic lupus erythematosus, asthma, and inflammatory bowel disease. It is one of the leading companies in China's autoimmune and allergic disease sector.
In April this year, QYUNS-B announced signing a licensing agreement with Caldera Therapeutics for QX030N, a long-acting autoimmune dual antibody in preclinical stage independently developed by QYUNS-B, granting Caldera exclusive global rights to develop and commercialize QX030N. QYUNS-B reaped substantial rewards: a one-time upfront payment of US$10 million, approximately 24.88% equity stake in Caldera, and up to US$545 million in additional payments under specific conditions plus tiered royalties on net sales.
Additionally, the company previously stated during its 2024 annual results conference that Celecoxib, as a biosimilar drug, has automatically entered the medical insurance catalog. Combined with Huadong Medicine's strong sales capabilities, the product is expected to achieve sales of 300 million yuan in 2025, with peak sales of 1.5 billion to 2 billion yuan. After the product generates sales profits, QYUNS-B's revenue share will be included in the company's income.